Fresh analysis reveals that patients who come off new weight-loss injections like Wegovy and Mounjaro can put back on reduced body mass far faster than those who end conventional lifestyle regimens.
Findings released in a prominent health publication demonstrates that while obese individuals can lose about a fifth of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Individuals using such medications should be informed of the potential of rapid rebound weight gain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery suggests a return to starting weight in about one and a half years.
Weighing Treatments
The study, which examined dozens of trials involving over 9,000 of patients, compared the results of GLP-1 agonists with other pills.
Researchers emphasize that individuals who shed pounds through dieting generally see a less rapid creep back—perhaps 100 grams monthly—post-intervention.
Explaining the Rapid Regain
Doctors suggest the way of the jabs accounts for the amplified regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone concentrations far above than the body's typical production might result in the body to produce less of its endogenous hormone, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is uncontrolled, making binge eating far more likely."
A Chronic Issue?
Medical guidelines recommend the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, considering the high risk of relapse, the therapy should be considered life-long.
This perspective is supported by pharmaceutical companies, who say that the results "emphasize the persistent character of excess weight," akin to managing diseases like diabetes.
Patient Testimonies
Individuals who have stopped the jabs report a sudden resurgence of cravings.
"I experienced something activating and you're instantly ravenous," described a patient.
This difficulty is compounded if individuals have not developed sustainable dietary or behavioural modifications during therapy.
Widespread Adoption
Recent estimates suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Use is more common among women compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, clinicians caution that while the jabs are powerful tools for shedding pounds, they are not a permanent cure and maintained weight loss likely depends on ongoing behavioural management.
